Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering

INTRODUCTION: Relationships between glycemic-lowering effects of sodium glucose co-transporter 2 inhibitors and impact on kidney and cardiovascular outcomes are uncertain. RESEARCH DESIGN AND METHODS: We analyzed 4395 individuals with prebaseline and postbaseline hemoglobin A1c (HbA1c) randomized to...

Descripción completa

Detalles Bibliográficos
Autores principales: Charytan, David M, Mahaffey, Kenneth W, Jardine, Meg J, Cannon, Christopher P, Neal, Bruce, Lambers Heerspink, Hiddo J, Agarwal, Rajiv, Bakris, George L, de Zeeuw, Dick, Levin, Adeera, Pollock, Carol, Zhang, Hong, Zinman, Bernard, Rosenthal, Norman, Perkovic, Vlado, Di Tanna, Gian Luca, Yu, Jie, Rogers, Kris, Arnott, Clare, Wheeler, David C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Cardiovascular and Metabolic Risk
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10277062/
https://www.ncbi.nlm.nih.gov/pubmed/37311602
http://dx.doi.org/10.1136/bmjdrc-2022-003270

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10277062/
https://www.ncbi.nlm.nih.gov/pubmed/37311602
http://dx.doi.org/10.1136/bmjdrc-2022-003270

Ejemplares similares